NUTENT THERAPEUTICS, INC.
BOCA RATON, FLORIDA

About - Nutraceuticals Supported by Clinical Trials | Nutent Therapeutics COMPANY BACKGROUND Nutent Therapeutics, Inc. was incorporated in January, 2017 in the state of Delaware as a C-corporation. It will be located in Boca Raton, Florida and was formed through a spin-off from Levolta Pharmaceuticals, Inc. The Company has three founders: Richard P. Becker Jr. (CEO of Levolta and Nutent), Ketan Desai (CMO of Levolta) and Renee Stewart (CSO of Levolta). All three of the founders also represent the current shareholders within the Company. The Company is currently in the pre-revenue phase though anticipates the commercial launch of VOLT03 in Q2 2018. Revenues will be reinvested towards driving key milestones and business development for the Company. VOLT03 was in-licensed from Levolta Pharmaceuticals, Inc. in April 2017. Company Strengths Nutent will be the first company to promote their nutraceutical portfolio through the support of clinical trials. The clinical data will not only support label promotional claims in the U.S. but also required for approval in International markets. Mr. Becker has a wealth of experience in various aspects of the pharmaceutical industry including 22 years in commercializing products as an executive for companies such as BASF, Bayer, Merck, and Novartis. Mr. Becker was appointed to his current position in January, 2017 and has more than 20 years of experience in the pharmaceutical and biotechnology industry. Mr. Becker has successfully led large, medium and entrepreneurial companies to substantial growth in fiercely competitive markets. He is currently the CEO of Levolta Pharmaceuticals, a clinical-stage company with a phase III product targeting knee osteoarthritis. During his career, he has assumed progressive commercial leadership roles for Alcon, Merck, Novartis, OSI Pharmaceuticals, Bayer and BASF. He has launched six products, commercially developed three others, built organizations and obtained investor financing as a senior-level executive. Mr. Becker received a Masters of Business Administration from Drexel University, a Bachelor of Pharmacy degree from the Philadelphia College of Pharmacy & Sciences and has completed an Executive Management Program at the University Of Pennsylvania’s Wharton Business School. Nutent Therapeutics will commercialize pharmaceutical-grade products that will be differentiated through successful clinical trials across multiple therapeutic areas. Mr. Becker was appointed to his current position in January, 2017 and has more than 20 years of experience in the pharmaceutical and biotechnology industry. Mr. Becker has successfully led large, medium and entrepreneurial companies to substantial growth in fiercely competitive markets. He is currently the CEO of Levolta Pharmaceuticals, a clinical-stage company with a phase III product targeting knee osteoarthritis. Nutent Therapeutics will commercialize pharmaceutical-grade products that will be differentiated through successful clinical trials across multiple therapeutic areas.